503A vs 503B

Walk into a CVS in any city and ask for a vial of semaglutide compounded for your specific dose. You will be told, with some bewilderment, that they do not do that. They cannot do that. The chemistry is straightforward. The reason it cannot happen at a chain pharmacy is not chemistry. It is law.

Two sections of the Federal Food, Drug, and Cosmetic Act, written years apart and forced to grow up by an outbreak that killed sixty-four people, decide where your peptide can be made and who is allowed to make it. They are called Section 503A and Section 503B. Together they describe the entire universe of compounded medications in the United States. Together they decide whether the peptide in your refrigerator is medicine or something else.

What "compounding" actually means

A compounded drug is a medication prepared for a specific patient by a licensed pharmacy, usually because the manufactured version does not exist or does not meet that patient's needs. A child who cannot swallow a tablet might need the drug in liquid form. A patient allergic to a dye in a commercial product might need a dye-free version. A peptide therapy, dosed precisely for one patient and not produced as a finished commercial drug, is compounded.

This is an old practice. American pharmacy was almost entirely compounding until industrial pharmaceutical manufacturing took over in the twentieth century. What modern law had to do was draw clear lines around it: who can compound, for whom, at what scale, and to what standards. Section 503A and Section 503B are those lines.

1997, 2012, 2013

The first formal compounding framework was the FDA Modernization Act of 1997. It carved out an exemption from full drug-manufacturer regulation for pharmacies that compounded individual prescriptions. That exemption became Section 503A. For the next fifteen years, it described essentially all of legitimate compounding in the United States.

In 2012, a Massachusetts pharmacy called the New England Compounding Center shipped contaminated methylprednisolone injections to clinics in twenty-three states. Sixty-four patients died from fungal meningitis. Seven hundred and ninety-three more became seriously ill. The pharmacy's owner was eventually convicted on federal charges. The outbreak made it clear that 503A had been written for a smaller world, one in which compounding pharmacies prepared individual prescriptions rather than industrial-scale batches shipped in bulk.

Congress responded the next year with the Drug Quality and Security Act of 2013. The law added a second category, Section 503B, for facilities that compound at scale without patient-specific prescriptions. The two sections, taken together, became the law that governs every legitimate compounded vial in the country.

503A: the patient-specific compounder

A 503A pharmacy compounds medications for individual named patients with valid prescriptions. Every vial leaving the pharmacy carries a prescription label showing the patient's name, the prescriber, the dose, and the expiration date. State boards of pharmacy regulate 503A pharmacies as their primary oversight body. The FDA also has authority, especially when interstate shipping crosses certain volume thresholds, but day-to-day inspection happens at the state level.

Sterile compounded products, including all injectable peptides, must be made under USP General Chapter 797, which sets requirements for cleanroom design, air-quality testing, sterilization, personnel training, and final-product release. Each batch is documented. Each prescription is filled against a specific patient's record. This is where the great majority of compounded peptides for individual patients come from in the United States.

503B: the outsourcing facility

A 503B facility, formally called an outsourcing facility, compounds at scale without patient-specific prescriptions. The customer is typically a clinic or hospital that needs office-stock supply rather than a single named patient. To make this legal, 503B facilities must operate under Current Good Manufacturing Practice standards, the same framework used by industrial pharmaceutical manufacturers. They are inspected by the FDA directly, on a published schedule, the way a manufacturer is inspected.

503B facilities can ship interstate without the volume limits that apply to 503A pharmacies. They register voluntarily with the FDA and submit production reports. The standards are higher, the federal oversight is more direct, and the volume per facility is much larger.

Why the distinction matters for your prescription

Two practical things follow from this legal architecture. First, your peptide prescription has to be written specifically for you, by a licensed clinician, to be filled at a 503A pharmacy. There is no "self-prescribed" route, and the absence of a prescription is what legally distinguishes a compounded medication from a "research grade" chemical. Second, the pharmacy that fills your prescription has a name, a license, an inspection record, and a state board accountable for its conduct. Any of this can be audited if you want to.

Both of these are features, not friction. They are the reason a compounded peptide is treated as medicine and the reason your name is on the label.

Where pru sits in this framework

At pru, every prescription is filled at a state-licensed 503A pharmacy that we have evaluated in detail. The pharmacy has a name. The pharmacy has a license number. The pharmacy is inspected by its state board. Each batch ships with a Certificate of Analysis. We chose 503A as the framework for individual patient prescriptions because that is what the law was designed for, and because the level of patient-specific care it requires is the level we want delivered to every pru patient.

The two short numbers are the entire architecture. They explain why CVS does not sell peptides, why your prescription has to be written a specific way, and why the pharmacy filling it is named, licensed, and accountable. The next time you read a vial label, those numbers are the reason it says what it says.